Cancer/testis antigen 2
Cancer/testis antigen 2 (37-50) is a synthetic peptide fragment derived from the immunologically significant cancer/testis antigen family, specifically encompassing amino acid residues 37 to 50 of the CTAG2 protein sequence. This peptide is characterized by its restricted expression profile, predominantly found in various malignancies and in testicular germ cells, but not in most normal somatic tissues. The unique immunogenic properties and tumor-associated expression of CTAG2 peptides have made them valuable molecular tools in cancer immunology, epitope mapping, and antigen presentation research. As a defined peptide sequence, Cancer/testis antigen 2 (37-50) enables precise experimental manipulation for studies exploring antigen processing, T-cell recognition, and the molecular mechanisms underlying tumor-specific immune responses.
Epitope mapping: Researchers utilize this peptide to delineate specific T-cell epitopes within the CTAG2 protein, enabling the identification of immunologically relevant regions recognized by cytotoxic T lymphocytes. By employing the 37-50 peptide fragment in functional assays such as ELISPOT, intracellular cytokine staining, or tetramer analysis, investigators can characterize antigen-specific T-cell populations and refine understanding of peptide-MHC interactions. This approach is instrumental in dissecting the immunodominance hierarchy and in guiding the rational design of peptide-based immunological reagents.
Antigen presentation studies: The defined sequence of Cancer/testis antigen 2 (37-50) supports detailed investigations into the mechanisms by which tumor antigens are processed and presented by major histocompatibility complex (MHC) molecules. By loading this peptide onto antigen-presenting cells or incorporating it into in vitro presentation assays, researchers can assess peptide binding affinity, stability, and the efficiency of T-cell activation. Such studies provide critical insights into the determinants of effective antigen presentation in the context of tumor immunology.
Peptide-based assay development: The synthetic nature and well-defined sequence of this CTAG2-derived peptide make it an ideal standard for developing and validating immunoassays targeting cancer/testis antigens. It serves as a positive control in enzyme-linked immunosorbent assays (ELISA), T-cell proliferation assays, or cytotoxicity assays, ensuring assay specificity and sensitivity. Utilizing this peptide in assay calibration enhances reproducibility and comparability across experimental platforms, facilitating robust detection of antigen-specific immune responses.
Vaccine research models: The immunogenicity of CTAG2 peptides, including the 37-50 region, underpins their use as experimental components in preclinical cancer vaccine research. Investigators incorporate this peptide into model systems to evaluate its capacity to elicit antigen-specific T-cell responses, optimize adjuvant formulations, and study the parameters influencing immune priming. These studies inform the broader understanding of peptide-based vaccine strategies, supporting the advancement of next-generation immunotherapeutic approaches.
Structural and biophysical analysis: The defined sequence of Cancer/testis antigen 2 (37-50) enables detailed structural and biophysical studies to elucidate peptide conformation, stability, and interaction with MHC molecules or antibodies. Techniques such as circular dichroism, NMR spectroscopy, or crystallography can be applied to this peptide to reveal structural determinants that influence immunogenicity and molecular recognition. Such analyses contribute to the rational design of improved peptide analogs and the broader field of structure-guided immunogen development.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More